---
title: "Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development | NXTS Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286779910.md"
description: "Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development | NXTS Stock News"
datetime: "2026-05-18T05:30:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286779910.md)
  - [en](https://longbridge.com/en/news/286779910.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286779910.md)
---

# Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development | NXTS Stock News

Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development | NXTS Stock News

### Related Stocks

- [NXTS.US](https://longbridge.com/en/quote/NXTS.US.md)

## Related News & Research

- [Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone | NXTS Stock News](https://longbridge.com/en/news/286248783.md)
- [VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME | VBIO Stock News](https://longbridge.com/en/news/286964504.md)
- [Activist Elliott Takes Major Stake in Bio-Rad — Can It Boost BIO Stock Price?](https://longbridge.com/en/news/286737807.md)
- [Kyntra Bio Rocked by CEO’s Sudden Insider Stock Sale](https://longbridge.com/en/news/286847501.md)
- [Valion Bio Reports Q1 Results, Advances Entolimod Platform](https://longbridge.com/en/news/286477206.md)